Figures & data
Figure 1 Fabrication of lipid-coated calcium phosphate nanoparticles.
Abbreviations: CaP, calcium phosphate; LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid.
![Figure 1 Fabrication of lipid-coated calcium phosphate nanoparticles.Abbreviations: CaP, calcium phosphate; LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid.](/cms/asset/6032fb6b-9645-44b2-b1d4-dcb8c11285fb/dijn_a_38928_f0001_c.jpg)
Figure 2 (A) Effect of poly (I:C) on particle size of LCP without zoledronic acid. (B) Effect of ratio of poly (I:C) to zoledronic acid on particle size of LCP.
Abbreviations: LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid; zol, zoledronic acid.
![Figure 2 (A) Effect of poly (I:C) on particle size of LCP without zoledronic acid. (B) Effect of ratio of poly (I:C) to zoledronic acid on particle size of LCP.Abbreviations: LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid; zol, zoledronic acid.](/cms/asset/e2c89c45-17a8-4e3a-8b19-68f9c3ec2779/dijn_a_38928_f0002_b.jpg)
Table 1 Diameter, polydispersity index, zeta potential, and encapsulation efficiency of different nanoparticles
Figure 3 Size distribution of LCP-poly (I:C)-zoledronic acid.
Abbreviations: LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid.
![Figure 3 Size distribution of LCP-poly (I:C)-zoledronic acid.Abbreviations: LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid.](/cms/asset/9757bfe7-52ee-4ff7-9bf2-35bc052bcd30/dijn_a_38928_f0003_c.jpg)
Figure 4 Change of particle size of LCP-poly (I:C)-zoledronic acid and CaP-poly (I:C)-zoledronic acid at 4°C within 30 days.
Abbreviations: CaP, calcium phosphate; LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid; ZOL, zoledronic acid.
![Figure 4 Change of particle size of LCP-poly (I:C)-zoledronic acid and CaP-poly (I:C)-zoledronic acid at 4°C within 30 days.Abbreviations: CaP, calcium phosphate; LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid; ZOL, zoledronic acid.](/cms/asset/a99c2c17-703f-4fd1-a4dd-59851a605c6c/dijn_a_38928_f0004_c.jpg)
Figure 5 In vitro cytotoxicity of free poly (I:C), CaP-poly (I:C), Lipoplex-poly (I:C), and LCP-poly (I:C) in a B16BL6 cell line, with a poly (I:C) concentration of 0.5 μg/mL.
Notes: *P < 0.05, compared with free poly (I:C); **P < 0.05, compared with lipoplex-poly (I:C).
Abbreviations: CaP, calcium phosphate; LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid.
![Figure 5 In vitro cytotoxicity of free poly (I:C), CaP-poly (I:C), Lipoplex-poly (I:C), and LCP-poly (I:C) in a B16BL6 cell line, with a poly (I:C) concentration of 0.5 μg/mL.Notes: *P < 0.05, compared with free poly (I:C); **P < 0.05, compared with lipoplex-poly (I:C).Abbreviations: CaP, calcium phosphate; LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid.](/cms/asset/7761af22-50ab-49cc-a52a-075a335a5ea1/dijn_a_38928_f0005_b.jpg)
Figure 6 In vitro cytotoxicity of LCP-poly (I:C)-zoledronic acid in B16BL6 cell line with different weight ratios of poly (I:C) to zoledronic acid.
Notes: The concentration of total drugs (poly (I:C) + zoledronic acid) was 0.5 μg/mL. *P < 0.05, compared with the ratio of 3/0; **P < 0.01, compared with the ratio of 3:0.
Abbreviations: LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid; ZOL, zoledronic acid.
![Figure 6 In vitro cytotoxicity of LCP-poly (I:C)-zoledronic acid in B16BL6 cell line with different weight ratios of poly (I:C) to zoledronic acid.Notes: The concentration of total drugs (poly (I:C) + zoledronic acid) was 0.5 μg/mL. *P < 0.05, compared with the ratio of 3/0; **P < 0.01, compared with the ratio of 3:0.Abbreviations: LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid; ZOL, zoledronic acid.](/cms/asset/3c04c53a-0fc4-4d80-9845-4fc63ab3ee24/dijn_a_38928_f0006_b.jpg)
Figure 7 Tumor growth inhibition by poly (I:C) and zoledronic acid codelivered by LCP in melanoma-bearing mice.
Notes: *P < 0.05 compared with PBS; **P < 0.01 compared with PBS.
Abbreviations: LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid; ZOL, zoledronic acid; PBS, phosphate-buffered solution.
![Figure 7 Tumor growth inhibition by poly (I:C) and zoledronic acid codelivered by LCP in melanoma-bearing mice.Notes: *P < 0.05 compared with PBS; **P < 0.01 compared with PBS.Abbreviations: LCP, lipid-coated calcium phosphate nanoparticles; poly (I:C), polyinosinic acid-polycytidylic acid; ZOL, zoledronic acid; PBS, phosphate-buffered solution.](/cms/asset/203ef4f6-889e-4ff4-86e8-7d7323d30235/dijn_a_38928_f0007_b.jpg)